AR064356A1 - TRPV1 BENZOIMIDAZOLIC INHIBITORS - Google Patents
TRPV1 BENZOIMIDAZOLIC INHIBITORSInfo
- Publication number
- AR064356A1 AR064356A1 ARP070105626A ARP070105626A AR064356A1 AR 064356 A1 AR064356 A1 AR 064356A1 AR P070105626 A ARP070105626 A AR P070105626A AR P070105626 A ARP070105626 A AR P070105626A AR 064356 A1 AR064356 A1 AR 064356A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- 2amino
- cycloalkyl
- group
- Prior art date
Links
- 102000003566 TRPV1 Human genes 0.000 title 1
- 101150016206 Trpv1 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 6
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 abstract 4
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 4
- 125000006598 aminocarbonylamino group Chemical group 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 abstract 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 3
- -1 1,2,3,4-tetrahydro-naphthalenyl Chemical group 0.000 abstract 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000004741 (C1-C6) haloalkylsulfonyl group Chemical group 0.000 abstract 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/50—1,3-Diazoles; Hydrogenated 1,3-diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Pest Control & Pesticides (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Agronomy & Crop Science (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicacion 1: Un compuesto de formula (1), y una de sus formas, en los cuales: las líneas punteadas entre las posiciones 1, 2 y 3 en la formula (1) indican las posiciones de un doble enlace tautomérico, en los cuales cuando se forma un doble enlace entre las posiciones 1 y 2, entonces R3b está presente, y en los cuales, cuando se forma un doble enlace entre las posiciones 2 y 3, entonces R3a está presente; p es 0, 1 o 2; q es 0, 1 o 2; r es 0, 1, 2 o 3; L es -X-alquilo C1-3- o -alquilo C1-3-Y-, donde cada caso del alquilo está perfluorado en forma opcional; X e Y son cada uno O, S, SO, SO2 o NR6; A1 se selecciona del grupo formado por indanilo, 1,2,3,4-tetrahidro-naftalenilo, fenilo, naftilo, benzo[1,3]dioxolilo, piridinilo y quinolinilo; R1 es hidrogeno, hidroxi, halogeno, alquilo C1-6, alcoxi C1-6, alquiltio C1-6, alquilsulfonilo C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-4, cicloalquil C3-8-alcoxi C1-4, cicloalquiloxi C3-8, amino, (alquil C1-6)1-2amino, (cicloalquil C3-8)1-2amino, (cicloalquil C3-8-alquil C1-4)1-2amino, ciano, alquilcarbonilo C1-6, alcoxicarbonilo C1-6, aminocarbonilo, (alquil C1-6)1-2aminocarbonilo, alquilcarbonilamino C1-6, aminocarbonil-alquilo C1-6, (alquil C16)1-2aminocarbonil- alquilo C1-6, alcoxi C1-6-aminocarbonil-alquilo C1-6, alcoxicarbonilamino C1-6, aminocarbonilamino, (alquil C1-6)1-2aminocarbonilamino, alquilsulfonilamino C1-6, aminosulfonilo o (alquil C1-4)1-2aminosulfonilo, donde cada caso del alquilo está sustituido en forma opcional con uno, dos o tres sustituyentes seleccionados en forma independiente del grupo formado por alcoxi C1-8, amino, (alquil C1-4)1-2amino, alquilcarbonilamino C1-6, alcoxicarbonilamino C1-6, aminocarbonilamino, (alquil C1- 6)1-2aminocarbonilamino, alquilsulfonilamino C1-6, halogeno, oxo e hidroxi, y en los cuales, cada caso del alquilo y el alcoxi está perfluorado en forma opcional; R2 se selecciona, cada uno, del grupo que consiste en halogeno, alquilo C1-4, alcoxi C1-4, alquilsulfonilo C1-4, nitro, (alquil C1-4)1-2amino y ciano, donde cada caso del alquilo y alcoxi está perfluorado en forma opcional; R3a y R3b se seleccionan, cada uno, del grupo que consiste en hidrogeno y alquilo C1-4; R4 es cada uno halogeno, nitro, ciano, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6, haloalcoxi C1-6, alcoxi C1-6-alquilo C1-6, alquiltio C1-6, haloalquiltio C1-6, alquilsulfonilo C1-6, haloalquilsulfonilo C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-4, cicloalquil C3-8-alcoxi C1-4, cicloalquiloxi C3-8-, amino, (alquil C1-6)1-2amino, (cicloalquil C3-8)1-2amino, (cicloalquil C3-8-alquil C1-4)1-2amino, ciano, alquilcarbonilo C1-6, alcoxicarbonilo C1-6, alcoxicarbonil C1-6-alquilo C1-6, aminocarbonilo, (alquil C1-6)1-2aminocarbonilo, alquilcarbonilamino C1-6, alcoxicarbonilamino C1-6, aminocarbonilamino, (alquil C1-6)1-2aminocarboniIamino, alquilsulfonilamino C1-6, aminosulfonilo o (alquil C1-4)1-2aminosulfonilo, donde cada caso del alquilo y alcoxi está perfluorado en forma opcional; R5 se selecciona del grupo formado por halogeno, hidroxi, alquilo C1-4, haloalquilo C1-4, hidroxialquilo C1-4, alcoxi C1-4, alquilsulfonilo C1-4, nitro, alquilcarbonilo C1-6, alcoxicarbonilo C1-6, amino, (alquil C1-4)1-2amino, alquilcarbonilamino C1-6, alquilsulfonilamino C1-6, aminosulfonilo, (alquil C1-6)1-2aminosulfonilo y ciano, donde cada caso del alquilo y alcoxi está perfluorado en forma opcional; y R6 es un sustituyente seleccionado del grupo que consiste en hidrogeno y alquilo C1-4 perfluorado en forma opcional.Claim 1: A compound of formula (1), and one of its forms, in which: the dashed lines between positions 1, 2 and 3 in formula (1) indicate the positions of a tautomeric double bond, in which when a double bond is formed between positions 1 and 2, then R3b is present, and in which, when a double bond is formed between positions 2 and 3, then R3a is present; p is 0, 1 or 2; q is 0, 1 or 2; r is 0, 1, 2 or 3; L is -X-C1-3alkyl- or -C1-3alkyl-, where each case of the alkyl is optionally perfluorinated; X and Y are each O, S, SO, SO2 or NR6; A1 is selected from the group consisting of indanyl, 1,2,3,4-tetrahydro-naphthalenyl, phenyl, naphthyl, benzo [1,3] dioxolyl, pyridinyl and quinolinyl; R 1 is hydrogen, hydroxy, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 alkylsulfonyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-4 alkyl, C 3-8 cycloalkyl -4, C3-8 cycloalkyloxy, amino, (C1-6 alkyl) 1-2amino, (C3-8 cycloalkyl) 1-2amino, (C3-8 cycloalkyl-C1-4 alkyl) 1-2amino, cyano, C1- alkylcarbonyl 6, C1-6 alkoxycarbonyl, aminocarbonyl, (C1-6 alkyl) 1-2aminocarbonyl, C1-6 alkylcarbonylamino, C1-6 alkylcarbonyl, (C16 alkyl) 1-2aminocarbonyl- C1-6 alkyl, C1-6 alkoxycarbonyl - C1-6 alkyl, C1-6 alkoxycarbonylamino, aminocarbonylamino, (C1-6 alkyl) 1-2aminocarbonylamino, C1-6 alkylsulfonylamino, aminosulfonyl or (C1-4 alkyl) 1-2aminosulfonyl, where each case of the alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C1-8 alkoxy, amino, (C1-4 alkyl) 1-2amino, C1-6 alkylcarbonylamino, C1-6 alkoxycarbonylamino, aminocarbonylamino, (C1-6 alkyl) 1-2 aminocarbonylamino , C1-6 alkylsulfonylamino, halogen, oxo and hydroxy, and in which, each case of the alkyl and the alkoxy is optionally perfluorinated; R2 is each selected from the group consisting of halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylsulfonyl, nitro, (C1-4 alkyl) 1-2amino and cyano, where each case of the alkyl and alkoxy is optionally perfluorinated; R3a and R3b are each selected from the group consisting of hydrogen and C1-4 alkyl; R4 is each halogen, nitro, cyano, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkoxy-C1-6 alkyl, C1-6 alkylthio, C1-6 haloalkyl, C 1-6 alkylsulfonyl, C 1-6 haloalkylsulfonyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-4 alkoxy, C 3-8 cycloalkyloxy, amino, (C 1-6 alkyl) 1 -2amino, (C3-8 cycloalkyl) 1-2amino, (C3-8 cycloalkylC 1-4 alkyl) 1-2amino, cyano, C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkoxycarbonyl, C1-6 alkyl, aminocarbonyl, (C1-6 alkyl) 1-2aminocarbonyl, C1-6 alkylcarbonylamino, C1-6 alkoxycarbonylamino, aminocarbonylamino, (C1-6 alkyl) 1-2aminocarbonylamino, C1-6 alkylsulfonylamino, aminosulfonyl or (C1-4 alkyl) 1-2aminosulfonyl , where each case of the alkyl and alkoxy is optionally perfluorinated; R5 is selected from the group consisting of halogen, hydroxy, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxy, C1-4 alkylsulfonyl, nitro, C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, amino, (C1-4 alkyl) 1-2amino, C1-6 alkylcarbonylamino, C1-6 alkylsulfonylamino, aminosulfonyl, (C1-6 alkyl) 1-2aminosulfonyl and cyano, where each case of the alkyl and alkoxy is optionally perfluorinated; and R6 is a substituent selected from the group consisting of hydrogen and optionally perfluorinated C1-4 alkyl.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87021206P | 2006-12-15 | 2006-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064356A1 true AR064356A1 (en) | 2009-04-01 |
Family
ID=39536675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105626A AR064356A1 (en) | 2006-12-15 | 2007-12-14 | TRPV1 BENZOIMIDAZOLIC INHIBITORS |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7612211B2 (en) |
| EP (1) | EP2124563B1 (en) |
| JP (1) | JP5746471B2 (en) |
| KR (1) | KR101503286B1 (en) |
| AR (1) | AR064356A1 (en) |
| AU (1) | AU2007333990A1 (en) |
| BR (1) | BRPI0721169A2 (en) |
| CA (1) | CA2672856C (en) |
| CL (1) | CL2007003636A1 (en) |
| ES (1) | ES2551709T3 (en) |
| MX (1) | MX2009006473A (en) |
| NZ (1) | NZ598485A (en) |
| PE (1) | PE20081383A1 (en) |
| TW (1) | TWI425943B (en) |
| UY (1) | UY30787A1 (en) |
| WO (1) | WO2008076752A1 (en) |
| ZA (1) | ZA200904920B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7951829B2 (en) * | 2006-05-03 | 2011-05-31 | Janssen Pharmaceutica Nv | Benzimidazole modulators of VR1 |
| US20100144717A1 (en) * | 2006-12-15 | 2010-06-10 | Janelle Comita-Prevoir | 2-quinolinone and 2-quinoxalinone-derivatives and their use as antibacterial agents |
| CN101868443A (en) | 2007-09-20 | 2010-10-20 | 特拉维夫大学拉莫特有限公司 | N-phenylanthranilic acid derivatives and uses thereof |
| US8217060B2 (en) | 2009-05-15 | 2012-07-10 | Janssen Pharmaceutica, Nv | Benzimidazole derivatives useful as TRP M8 receptor modulators |
| EP2390245A1 (en) * | 2010-05-26 | 2011-11-30 | Nabriva Therapeutics AG | Enantiomerically pure amines |
| EP3009427B1 (en) | 2011-03-03 | 2019-12-18 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
| JP6311603B2 (en) * | 2012-06-22 | 2018-04-18 | 住友化学株式会社 | Fused heterocyclic compounds |
| EP2700431A1 (en) | 2012-08-24 | 2014-02-26 | AnalytiCon Discovery GmbH | Plant extracts for modulating TRPV1 function |
| LT6064B (en) | 2012-10-15 | 2014-08-25 | Vilniaus Universitetas | Fluorinated benzenesulfonamides as inhibitors of carbonic anhydrase |
| EP4483953A3 (en) | 2016-12-02 | 2025-03-19 | Symrise AG | Cosmetic blends |
| CA3077659A1 (en) | 2017-10-09 | 2019-04-18 | Ramot At Tel-Aviv University Ltd. | Modulators of potassium ion and trpv1 channels and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3182070A (en) * | 1962-05-24 | 1965-05-04 | Dow Chemical Co | Benzimidazole compounds |
| FR2766822B1 (en) * | 1997-07-30 | 2001-02-23 | Adir | NOVEL DERIVATIVES OF BENZIMIDAZOLE, BENZOXAZOLE AND BENZOTHIAZOLE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| US6299796B1 (en) | 1997-12-18 | 2001-10-09 | Fuji Photo Film Co., Ltd. | Styryl compound, method for the preparation thereof and electroluminescent element employing the same |
| AR041191A1 (en) | 2002-08-08 | 2005-05-04 | Amgen Inc | VANILLOID RECEIVER LINKS AND THEIR USE IN TREATMENTS |
| US20060172019A1 (en) | 2003-03-07 | 2006-08-03 | Ralston Stuart H | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
| JP2007509985A (en) | 2003-10-31 | 2007-04-19 | ニューロジェン・コーポレーション | Capsaicin receptor agonist |
| FR2880625B1 (en) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | N- (HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| US7429608B2 (en) * | 2005-01-20 | 2008-09-30 | Amgen Inc. | Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments |
| US7951829B2 (en) | 2006-05-03 | 2011-05-31 | Janssen Pharmaceutica Nv | Benzimidazole modulators of VR1 |
-
2007
- 2007-12-12 ES ES07865574.3T patent/ES2551709T3/en active Active
- 2007-12-12 EP EP07865574.3A patent/EP2124563B1/en active Active
- 2007-12-12 BR BRPI0721169-4A patent/BRPI0721169A2/en not_active IP Right Cessation
- 2007-12-12 MX MX2009006473A patent/MX2009006473A/en active IP Right Grant
- 2007-12-12 NZ NZ598485A patent/NZ598485A/en not_active IP Right Cessation
- 2007-12-12 JP JP2009541552A patent/JP5746471B2/en active Active
- 2007-12-12 US US11/954,647 patent/US7612211B2/en active Active
- 2007-12-12 KR KR1020097014675A patent/KR101503286B1/en active Active
- 2007-12-12 WO PCT/US2007/087228 patent/WO2008076752A1/en not_active Ceased
- 2007-12-12 CA CA2672856A patent/CA2672856C/en active Active
- 2007-12-12 AU AU2007333990A patent/AU2007333990A1/en not_active Abandoned
- 2007-12-13 UY UY30787A patent/UY30787A1/en unknown
- 2007-12-13 PE PE2007001787A patent/PE20081383A1/en not_active Application Discontinuation
- 2007-12-14 AR ARP070105626A patent/AR064356A1/en not_active Application Discontinuation
- 2007-12-14 CL CL200703636A patent/CL2007003636A1/en unknown
- 2007-12-14 TW TW096147795A patent/TWI425943B/en not_active IP Right Cessation
-
2009
- 2009-07-14 ZA ZA200904920A patent/ZA200904920B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0721169A2 (en) | 2014-03-18 |
| TW200843747A (en) | 2008-11-16 |
| NZ598485A (en) | 2013-08-30 |
| UY30787A1 (en) | 2008-07-03 |
| CA2672856C (en) | 2016-02-02 |
| ES2551709T3 (en) | 2015-11-23 |
| KR101503286B1 (en) | 2015-03-17 |
| EP2124563A1 (en) | 2009-12-02 |
| PE20081383A1 (en) | 2008-09-18 |
| ZA200904920B (en) | 2010-09-29 |
| US20080146637A1 (en) | 2008-06-19 |
| KR20090090386A (en) | 2009-08-25 |
| CA2672856A1 (en) | 2008-06-26 |
| CL2007003636A1 (en) | 2008-06-20 |
| EP2124563B1 (en) | 2015-07-29 |
| JP2010513298A (en) | 2010-04-30 |
| WO2008076752A1 (en) | 2008-06-26 |
| JP5746471B2 (en) | 2015-07-08 |
| MX2009006473A (en) | 2009-08-25 |
| EP2124563A4 (en) | 2011-04-20 |
| US7612211B2 (en) | 2009-11-03 |
| AU2007333990A1 (en) | 2008-06-26 |
| TWI425943B (en) | 2014-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064356A1 (en) | TRPV1 BENZOIMIDAZOLIC INHIBITORS | |
| AR060840A1 (en) | VR1 BENCIMIDAZOLIC MODULATORS | |
| AR056686A1 (en) | DIACILINDAZOL DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | |
| AR060158A1 (en) | DERIVATIVES OF AZOLOPIRIDIN-3-ONA AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | |
| AR037900A1 (en) | ALPHA-CYANOACRYLATES | |
| DK1888582T3 (en) | Imidazo and triazolopyridines as inhibitors of 11-beta-hydroxysteroid dehydrigenase | |
| NO20082517L (en) | Aminopyrimidines useful as kinase inhibitors | |
| EP2070633A4 (en) | LASER MACHINING PROCESS | |
| DK2377922T3 (en) | PDX1-expressing endoderm | |
| DK1931350T3 (en) | ADMINISTRATION OF DIPEPTIDYLPEPTIDASE INHIBITORS | |
| NO20090313L (en) | Derivatives and analogs of N-ethylquinolones and N-ethyllazakinolones | |
| DK3366278T3 (en) | AQUEOUS SUSPENSIONS OF TMC278 | |
| CU20090070A7 (en) | NEW DERIVATIVES OF SULFONAMIDE AS ANTAGONISTS OF BRADIQUININA | |
| DK1981875T3 (en) | SUBSTITUTED INDOLYLALKYLAMINODE DERIVATIVES AS INHIBITORS OF HISTONDEACETYLASE | |
| EP2084139A4 (en) | OXAZOLIDINIUM COMPOUNDS AND USE AS HYDRATE INHIBITORS | |
| AR051288A1 (en) | CONDENSED PIRAZOL DERIVATIVES, ITS PREPARATION AND THERAPEUTIC APPLICATION | |
| AR055613A1 (en) | CRYSTAL FORMS DELTA AND EPSILON OF IMATINIB MESILATE | |
| DK1750704T3 (en) | Urea Antagonists of P2Y1 Receptors Useful in the Treatment of Thrombotic Conditions | |
| AR052568A1 (en) | DERIVATIVES OF PIRAZOLO-PYRIMIDINE AS ANGLOSTS OF MGLUR2 | |
| MX2017013969A (en) | NEW GLASS OF URACILO COMPOUND. | |
| AR071902A1 (en) | 4- (3-ALQUILSULFINILBENZOIL) USEFUL PIRAZOLS AS HERBICIDE AGENTS AND PROCEDURE TO COMBAT INDESATED PLANTS. | |
| NL1030324A1 (en) | Sulfonyl benzimidazole derivatives. | |
| DK1776136T3 (en) | Treatment of conditions involving demyelination | |
| DK1954690T3 (en) | BENZAMIDE COMPOUNDS USED AS INHIBITORS OF HISTONDEACETYLASE | |
| EP1906243A4 (en) | ALKALI DEVELOPABLE, LIGHT SENSITIVE COLORED COMPOSITION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |